The role of Aurora-A in cancer stem cells
Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expres...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Li, Minle [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
4 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Urological Diseases of the Byzantine Emperors (330-1453) - 2011, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:98 ; year:2018 ; pages:89-92 ; extent:4 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.biocel.2018.03.007 |
|---|
| Katalog-ID: |
ELV042829070 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042829070 | ||
| 003 | DE-627 | ||
| 005 | 20230626002425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biocel.2018.03.007 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000212A.pica |
| 035 | |a (DE-627)ELV042829070 | ||
| 035 | |a (ELSEVIER)S1357-2725(18)30061-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 540 | |
| 082 | 0 | 4 | |a 540 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.85 |2 bkl | ||
| 100 | 1 | |a Li, Minle |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of Aurora-A in cancer stem cells |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. | ||
| 520 | |a Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. | ||
| 650 | 7 | |a Aurora-A inhibitors |2 Elsevier | |
| 650 | 7 | |a Aurora-A |2 Elsevier | |
| 650 | 7 | |a Cancer stem cells |2 Elsevier | |
| 700 | 1 | |a Gao, Keyu |4 oth | |
| 700 | 1 | |a Chu, Laili |4 oth | |
| 700 | 1 | |a Zheng, Junnian |4 oth | |
| 700 | 1 | |a Yang, Jing |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |t Urological Diseases of the Byzantine Emperors (330-1453) |d 2011 |g Amsterdam |w (DE-627)ELV010616845 |
| 773 | 1 | 8 | |g volume:98 |g year:2018 |g pages:89-92 |g extent:4 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.biocel.2018.03.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.85 |j Kardiologie |j Angiologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 98 |j 2018 |h 89-92 |g 4 | ||
| 953 | |2 045F |a 540 | ||
| author_variant |
m l ml |
|---|---|
| matchkey_str |
liminlegaokeyuchulailizhengjunnianyangji:2018----:hrloarranacr |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
44.85 |
| publishDate |
2018 |
| allfields |
10.1016/j.biocel.2018.03.007 doi GBV00000000000212A.pica (DE-627)ELV042829070 (ELSEVIER)S1357-2725(18)30061-X DE-627 ger DE-627 rakwb eng 540 540 DE-600 610 VZ 610 VZ 44.85 bkl Li, Minle verfasserin aut The role of Aurora-A in cancer stem cells 2018transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells Elsevier Gao, Keyu oth Chu, Laili oth Zheng, Junnian oth Yang, Jing oth Enthalten in Elsevier Urological Diseases of the Byzantine Emperors (330-1453) 2011 Amsterdam (DE-627)ELV010616845 volume:98 year:2018 pages:89-92 extent:4 https://doi.org/10.1016/j.biocel.2018.03.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 98 2018 89-92 4 045F 540 |
| spelling |
10.1016/j.biocel.2018.03.007 doi GBV00000000000212A.pica (DE-627)ELV042829070 (ELSEVIER)S1357-2725(18)30061-X DE-627 ger DE-627 rakwb eng 540 540 DE-600 610 VZ 610 VZ 44.85 bkl Li, Minle verfasserin aut The role of Aurora-A in cancer stem cells 2018transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells Elsevier Gao, Keyu oth Chu, Laili oth Zheng, Junnian oth Yang, Jing oth Enthalten in Elsevier Urological Diseases of the Byzantine Emperors (330-1453) 2011 Amsterdam (DE-627)ELV010616845 volume:98 year:2018 pages:89-92 extent:4 https://doi.org/10.1016/j.biocel.2018.03.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 98 2018 89-92 4 045F 540 |
| allfields_unstemmed |
10.1016/j.biocel.2018.03.007 doi GBV00000000000212A.pica (DE-627)ELV042829070 (ELSEVIER)S1357-2725(18)30061-X DE-627 ger DE-627 rakwb eng 540 540 DE-600 610 VZ 610 VZ 44.85 bkl Li, Minle verfasserin aut The role of Aurora-A in cancer stem cells 2018transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells Elsevier Gao, Keyu oth Chu, Laili oth Zheng, Junnian oth Yang, Jing oth Enthalten in Elsevier Urological Diseases of the Byzantine Emperors (330-1453) 2011 Amsterdam (DE-627)ELV010616845 volume:98 year:2018 pages:89-92 extent:4 https://doi.org/10.1016/j.biocel.2018.03.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 98 2018 89-92 4 045F 540 |
| allfieldsGer |
10.1016/j.biocel.2018.03.007 doi GBV00000000000212A.pica (DE-627)ELV042829070 (ELSEVIER)S1357-2725(18)30061-X DE-627 ger DE-627 rakwb eng 540 540 DE-600 610 VZ 610 VZ 44.85 bkl Li, Minle verfasserin aut The role of Aurora-A in cancer stem cells 2018transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells Elsevier Gao, Keyu oth Chu, Laili oth Zheng, Junnian oth Yang, Jing oth Enthalten in Elsevier Urological Diseases of the Byzantine Emperors (330-1453) 2011 Amsterdam (DE-627)ELV010616845 volume:98 year:2018 pages:89-92 extent:4 https://doi.org/10.1016/j.biocel.2018.03.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 98 2018 89-92 4 045F 540 |
| allfieldsSound |
10.1016/j.biocel.2018.03.007 doi GBV00000000000212A.pica (DE-627)ELV042829070 (ELSEVIER)S1357-2725(18)30061-X DE-627 ger DE-627 rakwb eng 540 540 DE-600 610 VZ 610 VZ 44.85 bkl Li, Minle verfasserin aut The role of Aurora-A in cancer stem cells 2018transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells Elsevier Gao, Keyu oth Chu, Laili oth Zheng, Junnian oth Yang, Jing oth Enthalten in Elsevier Urological Diseases of the Byzantine Emperors (330-1453) 2011 Amsterdam (DE-627)ELV010616845 volume:98 year:2018 pages:89-92 extent:4 https://doi.org/10.1016/j.biocel.2018.03.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 98 2018 89-92 4 045F 540 |
| language |
English |
| source |
Enthalten in Urological Diseases of the Byzantine Emperors (330-1453) Amsterdam volume:98 year:2018 pages:89-92 extent:4 |
| sourceStr |
Enthalten in Urological Diseases of the Byzantine Emperors (330-1453) Amsterdam volume:98 year:2018 pages:89-92 extent:4 |
| format_phy_str_mv |
Article |
| bklname |
Kardiologie Angiologie |
| institution |
findex.gbv.de |
| topic_facet |
Aurora-A inhibitors Aurora-A Cancer stem cells |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Urological Diseases of the Byzantine Emperors (330-1453) |
| authorswithroles_txt_mv |
Li, Minle @@aut@@ Gao, Keyu @@oth@@ Chu, Laili @@oth@@ Zheng, Junnian @@oth@@ Yang, Jing @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV010616845 |
| dewey-sort |
3540 |
| id |
ELV042829070 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042829070</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626002425.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.biocel.2018.03.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000212A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042829070</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1357-2725(18)30061-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">540</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.85</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, Minle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The role of Aurora-A in cancer stem cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Aurora-A inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Aurora-A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer stem cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gao, Keyu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chu, Laili</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zheng, Junnian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Jing</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">Urological Diseases of the Byzantine Emperors (330-1453)</subfield><subfield code="d">2011</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV010616845</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:98</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:89-92</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.biocel.2018.03.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.85</subfield><subfield code="j">Kardiologie</subfield><subfield code="j">Angiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">98</subfield><subfield code="j">2018</subfield><subfield code="h">89-92</subfield><subfield code="g">4</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">540</subfield></datafield></record></collection>
|
| author |
Li, Minle |
| spellingShingle |
Li, Minle ddc 540 ddc 610 bkl 44.85 Elsevier Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells The role of Aurora-A in cancer stem cells |
| authorStr |
Li, Minle |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV010616845 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences 610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 540 DE-600 610 VZ 44.85 bkl The role of Aurora-A in cancer stem cells Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells Elsevier |
| topic |
ddc 540 ddc 610 bkl 44.85 Elsevier Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells |
| topic_unstemmed |
ddc 540 ddc 610 bkl 44.85 Elsevier Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells |
| topic_browse |
ddc 540 ddc 610 bkl 44.85 Elsevier Aurora-A inhibitors Elsevier Aurora-A Elsevier Cancer stem cells |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k g kg l c lc j z jz j y jy |
| hierarchy_parent_title |
Urological Diseases of the Byzantine Emperors (330-1453) |
| hierarchy_parent_id |
ELV010616845 |
| dewey-tens |
540 - Chemistry 610 - Medicine & health |
| hierarchy_top_title |
Urological Diseases of the Byzantine Emperors (330-1453) |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV010616845 |
| title |
The role of Aurora-A in cancer stem cells |
| ctrlnum |
(DE-627)ELV042829070 (ELSEVIER)S1357-2725(18)30061-X |
| title_full |
The role of Aurora-A in cancer stem cells |
| author_sort |
Li, Minle |
| journal |
Urological Diseases of the Byzantine Emperors (330-1453) |
| journalStr |
Urological Diseases of the Byzantine Emperors (330-1453) |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
89 |
| author_browse |
Li, Minle |
| container_volume |
98 |
| physical |
4 |
| class |
540 540 DE-600 610 VZ 44.85 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Li, Minle |
| doi_str_mv |
10.1016/j.biocel.2018.03.007 |
| dewey-full |
540 610 |
| title_sort |
role of aurora-a in cancer stem cells |
| title_auth |
The role of Aurora-A in cancer stem cells |
| abstract |
Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. |
| abstractGer |
Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. |
| abstract_unstemmed |
Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
The role of Aurora-A in cancer stem cells |
| url |
https://doi.org/10.1016/j.biocel.2018.03.007 |
| remote_bool |
true |
| author2 |
Gao, Keyu Chu, Laili Zheng, Junnian Yang, Jing |
| author2Str |
Gao, Keyu Chu, Laili Zheng, Junnian Yang, Jing |
| ppnlink |
ELV010616845 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.biocel.2018.03.007 |
| up_date |
2024-07-06T17:12:44.039Z |
| _version_ |
1803850575030255616 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042829070</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626002425.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.biocel.2018.03.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000212A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042829070</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1357-2725(18)30061-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">540</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.85</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, Minle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The role of Aurora-A in cancer stem cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aurora kinase A (Aurora-A), a member of the Aurora family of serine/threonine kinases, plays a critical role in multiple steps of mitotic progression, including microtubule stability during the G1 phase of the cell cycle, chromosome alignment and segregation, and cytokinesis and is aberrantly expressed in various types of human cancers. In addition to its classic functions, recent studies have indicated that Aurora-A is critical for controlling self-renewal of embryonic stem cells through negative regulation of p53. Additionally, aberrant expression of Aurora-A contributes to oncogenic transformation and induces stem cell-like properties in estrogen receptor α-positive breast cancer cells. Silencing of Aurora-A has been implicated in elimination of leukemia stem cells in vivo. Therefore, Aurora-A is an attractive target for cancer therapeutics and a growing number of small molecule inhibitors of Aurora-A have been developed. In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Aurora-A inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Aurora-A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer stem cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gao, Keyu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chu, Laili</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zheng, Junnian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Jing</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">Urological Diseases of the Byzantine Emperors (330-1453)</subfield><subfield code="d">2011</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV010616845</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:98</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:89-92</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.biocel.2018.03.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.85</subfield><subfield code="j">Kardiologie</subfield><subfield code="j">Angiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">98</subfield><subfield code="j">2018</subfield><subfield code="h">89-92</subfield><subfield code="g">4</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">540</subfield></datafield></record></collection>
|
| score |
7.401025 |